We aim to de-risk human causal biology early in drug discovery by understanding  patient-disease trajectories that reveal real world heterogeneity. We can identify and validate novel druggable targets mapped to patient need.

At the heart of our approach is deep integration across disciplines. Our teams work at the intersection of biology, chemistry and engineering, creating an interconnected R&D engine designed to turn patient insights into new medicines. 

We advance early-stage R&D to spark innovation, while our partners lead clinical development to deliver therapies to patients. By retaining royalties and using success-based economics, we foster shared risk and reward collaborations with aligned incentives.